PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI)

23 Dec 2019 09:30

RNS Number : 7971X
Arden Partners plc
23 December 2019
 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Arden Partners plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Open Orphan plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Open Orphan plc

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

20 December 2019

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

If YES, specify which:

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

0.1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

415,054

0.16%

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

415,054

0.16%

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

0.1p ordinary

Purchases

250,000

5.7p

5.7p

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

23 December 2019

Contact name:

Samantha Cook

Telephone number:

020 7614 5927

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEOEAPADAFNNFEF
Date   Source Headline
11th Jun 20207:00 amRNSMajor New Contract Signed
10th Jun 20205:40 pmRNSHolding(s) in Company
10th Jun 20205:35 pmRNSHolding(s) in Company
10th Jun 20205:30 pmRNSHolding(s) in Company
4th Jun 20207:00 amRNSLaunch of Covid-19 Antibody Testing
29th May 20208:00 amRNSEuronext Growth Dublin Notice
22nd May 202010:53 amRNSResults of Fundraising
22nd May 20207:01 amRNSPrimaryBid.com Offer
22nd May 20207:00 amRNSProposed Fundraising to raise up to £12 million
18th May 20209:05 amRNSSecond Price Monitoring Extn
18th May 20209:00 amRNSPrice Monitoring Extension
18th May 20207:00 amRNSUpdate on antibody test and share price movement
11th May 20207:00 amRNSAppointment of Joint Broker
11th May 20207:00 amRNSNew COVID-19 Antibody Testing Partnership
4th May 20207:00 amRNSMajor New Contract and Directorate Change
23rd Apr 20207:00 amRNSTesting of anti-viral for treating COVID-19
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
23rd Mar 20204:43 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:37 pmRNSPrice Monitoring Extension
20th Mar 20202:06 pmRNSSecond Price Monitoring Extn
20th Mar 20202:00 pmRNSPrice Monitoring Extension
16th Mar 20207:00 amRNSPublication of positive results in journal
12th Mar 20203:32 pmRNSHolding(s) in Company
12th Mar 20209:00 amRNSHolding(s) in Company
12th Mar 20208:00 amRNSEuronext Growth Dublin Notice
10th Mar 20207:00 amRNSPublication of Positive Results in Journal
9th Mar 20204:53 pmRNSCompletion of Compulsory Acquisition of Shares
9th Mar 20207:00 amRNSCoronavirus Challenge Study Model
6th Mar 20207:00 amRNSNew Contract
3rd Mar 20208:00 amRNSEuronext Growth Dublin Notice
2nd Mar 20203:25 pmRNSChange in Registered Office
27th Feb 20207:00 amRNSAppointment of new Director
26th Feb 20203:04 pmRNSResult of Rule 15 Offer and Total Voting Rights
21st Feb 20207:00 amRNSInvestor Event Attendance and Presentation
20th Feb 20207:00 amRNSAppointment of Chair of Advisory Board
20th Feb 20207:00 amRNSAppointment of Chair of Advisory Board
13th Feb 20207:00 amRNSAppointment of Group Chief Financial Officer
11th Feb 20208:00 amRNSEuronext Growth Dublin Notice
10th Feb 202011:17 amRNSValue the Markets Webinar
7th Feb 20206:08 pmRNSHolding(s) in Company
7th Feb 20203:42 pmRNSSignificant shareholder
7th Feb 20207:00 amRNSInvestor Event Attendance and Presentation
6th Feb 20209:30 amRNSTotal Voting Rights
6th Feb 20208:00 amRNSEuronext Growth Dublin Notice
6th Feb 20207:00 amRNSUpcoming Investor Events
5th Feb 202011:00 amRNSExercise of Warrants and Issue of Shares
3rd Feb 202010:30 amRNSNew Corporate Presentation
31st Jan 202011:23 amRNSResults of Placing and Subscription
31st Jan 20207:00 amRNSProposed Placing to raise a minimum of £5 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.